

PRODUCT INFORMATION

| | |
|---|---|
| Common Name | REGN2477 |
| Conjugate | Unconjugated |
| Synonyms | Activin beta-A chain INHBA, Activin A |
| Applications | ELISA |
| Endotoxin | Less than 1.0 EU/ μ g by the LAL method. For <1 EU/mg requirements, please contact us for customization. |
| Recommended Dilutions | ELISA 1:5000-10000 |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | Humanized |
| IgG type | Human IgG4 - Kappa |
| Reactivity | Human |
| Target | INHBA |
| Uniprot ID | P08476 |
| Description | Anti-INHBA(garetosmab biosimilar) mAb |
| Delivery | In Stock |
| Storage&Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature. |
| Sterility | Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μ m) prior to use. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |



Anti-INHBA(garetozmab biosimilar) mAb ELISA

0.2 μ g of Human Activin A protein per well




Figure 1. ELISA plate pre-coated by 2 μ g/mL (100 μ L/well) Human Activin A Protein can bind Anti-INHBA(garetozmab biosimilar) mAb (BME100519) in a linear range of 2.29-185.19 ng/mL.

